Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.82 |
| ▸ | BRD9 | Q9H8M2 | 10/20 | 0.73 |
| ▸ | CECR2 | Q9BXF3 | 3/20 | 0.72 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.49 |
| ▸ | BRD2 | P25440 | 1/20 | 0.49 |
| ▸ | EP300 | Q09472 | 1/20 | 0.49 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.49 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.49 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.49 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.49 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17749851 | 0.90 | BRD4 (1.00) | BRD4BRD9CECR2GABBR2BRD2 | |
| SCHEMBL17749852 | 0.90 | BRD4 (1.00) | BRD4BRD9CECR2GABBR2BRD2 | |
| SCHEMBL24363700 | 0.89 | BRD4 (0.86) | BRD4BRD9CECR2GABBR2BRD2 | |
| SCHEMBL17749870 | 0.84 | BRD9 (1.00) | BRD4BRD9CECR2 | |
| SCHEMBL17749755 | 0.84 | CECR2 (1.00) | BRD4BRD9CECR2 | |
| SCHEMBL29482219 | 0.84 | CECR2 (1.00) | BRD4BRD9CECR2 | |
| SCHEMBL29482221 | 0.84 | CECR2 (1.00) | BRD4BRD9CECR2 | |
| SCHEMBL24364270 | 0.76 | BRD4 (0.75) | BRD4BRD9CECR2GABBR2BRD2 | |
| SCHEMBL17749895 | 0.72 | BRD9 (0.81) | BRD4BRD9CECR2GABBR2BRD2 | |
| SCHEMBL30073548 | 0.72 | BRD9 (0.81) | BRD4BRD9CECR2GABBR2BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183009-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183009-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRPF3 | BRD4 1/4885BRD9 12/4885CECR2 246/4885 |
| US-20170340605-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRPF3 | BRD4 1/4885BRD9 12/4885CECR2 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.